193 related articles for article (PubMed ID: 23315986)
1. Mitochondrial delivery of bongkrekic acid using a MITO-Porter prevents the induction of apoptosis in human HeLa cells.
Yamada Y; Nakamura K; Furukawa R; Kawamura E; Moriwaki T; Matsumoto K; Okuda K; Shindo M; Harashima H
J Pharm Sci; 2013 Mar; 102(3):1008-15. PubMed ID: 23315986
[TBL] [Abstract][Full Text] [Related]
2. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
3. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.
Yamada Y; Harashima H
Biomaterials; 2012 Feb; 33(5):1589-95. PubMed ID: 22105068
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver.
Yamada Y; Nakamura K; Abe J; Hyodo M; Haga S; Ozaki M; Harashima H
J Control Release; 2015 Sep; 213():86-95. PubMed ID: 26160304
[TBL] [Abstract][Full Text] [Related]
5. Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.
Yamada Y; Harashima H
Methods Mol Biol; 2015; 1265():123-33. PubMed ID: 25634272
[TBL] [Abstract][Full Text] [Related]
6. Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells.
Abe J; Yamada Y; Harashima H
J Pharm Sci; 2016 Feb; 105(2):734-740. PubMed ID: 26523487
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
[TBL] [Abstract][Full Text] [Related]
8. Molecular design, synthesis, and evaluation of novel potent apoptosis inhibitors inspired from bongkrekic acid.
Okuda K; Hasui K; Abe M; Matsumoto K; Shindo M
Chem Res Toxicol; 2012 Oct; 25(10):2253-60. PubMed ID: 22998163
[TBL] [Abstract][Full Text] [Related]
9. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.
Yamada Y; Harashima H
Mitochondrion; 2013 Sep; 13(5):526-32. PubMed ID: 23000575
[TBL] [Abstract][Full Text] [Related]
10. A method for screening mitochondrial fusogenic envelopes for use in mitochondrial drug delivery.
Yamada Y; Harashima H
Methods Mol Biol; 2014; 1141():57-66. PubMed ID: 24567130
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
Yasuzaki Y; Yamada Y; Harashima H
Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
[TBL] [Abstract][Full Text] [Related]
12. MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2017; 240():457-472. PubMed ID: 27830347
[TBL] [Abstract][Full Text] [Related]
13. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
[TBL] [Abstract][Full Text] [Related]
14. The Use of a Microfluidic Device to Encapsulate a Poorly Water-Soluble Drug CoQ
Hibino M; Yamada Y; Fujishita N; Sato Y; Maeki M; Tokeshi M; Harashima H
J Pharm Sci; 2019 Aug; 108(8):2668-2676. PubMed ID: 30959057
[TBL] [Abstract][Full Text] [Related]
15. [Targeting mitochondria: innovation from mitochondrial drug delivery system (DDS) to mitochondrial medicine].
Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(10):1111-8. PubMed ID: 23037696
[TBL] [Abstract][Full Text] [Related]
16. Bongkrekic acid as a selective activator of the peroxisome proliferator-activated receptor γ (PPARγ) isoform.
Okazaki H; Takeda S; Ikeda E; Fukunishi Y; Ishii H; Taniguchi A; Tokuyasu M; Himeno T; Kakizoe K; Matsumoto K; Shindo M; Aramaki H
J Toxicol Sci; 2015 Apr; 40(2):223-33. PubMed ID: 25786526
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter.
Kawamura E; Yamada Y; Harashima H
Mitochondrion; 2013 Nov; 13(6):610-4. PubMed ID: 24012978
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
Furukawa R; Yamada Y; Kawamura E; Harashima H
Biomaterials; 2015 Jul; 57():107-15. PubMed ID: 25913255
[TBL] [Abstract][Full Text] [Related]
19. An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles.
Yamada Y; Fukuda Y; Harashima H
Mitochondrion; 2015 Sep; 24():50-5. PubMed ID: 26188112
[TBL] [Abstract][Full Text] [Related]
20. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion.
Yamada Y; Akita H; Kamiya H; Kogure K; Yamamoto T; Shinohara Y; Yamashita K; Kobayashi H; Kikuchi H; Harashima H
Biochim Biophys Acta; 2008 Feb; 1778(2):423-32. PubMed ID: 18054323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]